Tesamorelin ���景与作用机制 — Reference Sheet

By Editorial Desk · published 2025-09-08 · last reviewed 2025-10-07 · Faq

The short version of lipodystrophy fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2025-10-07. Anything still debated is marked as such rather than presented as settled.

tesamorelin 背景与作用机制

研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。

tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。

作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。

Molecular Background and Receptor Mechanism

Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.

Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.

Tesamorelin at a glance

Background and Clinical Profile

After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.

Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.

Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.

Related pages on this site

• Modular briefing
• Comprehensive guide
• Professional reference
• Sustainable analysis
• Scalable digest
• Sustainable primer
• Smart digest
• Focused primer

Identity and Development Background

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.

Background and Clinical Development

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Tesamorelin Background and Mechanism

Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.

A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.

Notes from published material

Despite initial resistance from American cattle ranchers, who believed the white hair of a freeze brand could be dyed to confuse ownership, the technique has since become a popular means of marking animals for identification worldwide.

== History == Benorterone was developed in the late 1950s, was first reported to possess antiandrogenic activity in 1964, and was investigated in clinical trials in the mid-to-late 1960s. It was the first known antiandrogen to be studied in humans. The drug was found to be effective in the treatment of acne, seborrhea, and hirsutism in women. In addition, unlike progestogenic antiandrogens such as cyproterone acetate, it seldom produced side effects in women and did not affect menstruation. However, in males, benorterone was not effective for acne, and produced high rates of gynecomastia (in 12 out of 13 or 92% of young men treated with 75 to 300 mg/day benorterone). Shortly following the observance of this side effect, it was withdrawn from clinical studies. Subsequently, cyproterone acetate, which has a greatly reduced risk of gynecomastia by virtue of its concomitant progestogenic and antigonadotropic actions (which results in suppression of estrogen levels), was developed instead and was introduced for medical use in 1973. In addition, spironolactone, a steroidal antimineralocorticoid that was introduced for medical use in 1959, was discovered to possess potent antiandrogenic activity in 1969, and became widely used clinically as an antiandrogen after its first use in an androgen-dependent condition in 1978.

=== Controversies === In January 2025, Paetongtarn revealed that she had nearly been victimized by a scam using a message in a voice sounding identical to another world leader whom she did not disclose in which the caller was asking for donations. On 24 March 2025, a no-confidence motion was filed against Paetongtarn by Leader of the Opposition Natthaphong Ruengpanyawut, who accused her of failing to address multiple issues and serving her family and Thaksin Shinawatra's interests. The motion failed to pass at a vote on 26 March, with Paetongtarn winning 319 votes.

Washington (Hb Lepore Washington, also known as Hb Lepore Boston or Hb Lepore Washington-Boston); most common in Italians from Southern Italy Baltimore (Hb Lepore Baltimore); first described in a family with African ancestry; most common in people from the Balkan countries, Albanians Croats, Serbs, Slovenes and Romanians. It has also been described in Turks and in regions of Spain and Portugal. A rare case of the Baltimore variety was discovered in an African American woman in the Bronx, New York and dubbed Hn Lepore-Bronx and another variety was discovered in the city of Saskatoon, Saskatchewan, Canada and dubbed Hb E-Lepore Saskatoon Hollandia (Hb Lepore Hollandia); identified in Papua New Guinea and Bangladesh.

Portal is a single-player first-person action/puzzle game that was first available as a part of The Orange Box as one of its three original new games. The game consists primarily of a series of puzzles, solved by creating portals which the player and simple objects can pass through in order to reach an exit point, under the supervision of an AI-programmed robot named GLaDOS. The portal system and the unusual physics it creates are the emphasis of the game. Portal was a surprise favorite of The Orange Box, receiving widespread praise and several Game of the Year awards.

Sources: en.wikipedia.org

Background from the literature

Both the δDs of sea water and the fractionations associated with hyptophyte biochemistry (εbio) are fairly well understood, so alkenones can be readily used to observe the secondary effect of salinity on δD. There is a well established positive linear correlation between salinity and εl/w, on the order of a ~3‰ change in fractionation per salinity unit. Hypothesized mechanisms for this effect include enrichment of D in intracellular water due to reduced exchange with extracellular water at higher salinity, removal of H from intracellular water due to increased production of solutes to maintain osmotic pressure at higher salinity, and lower haptophyte growth rates at higher salinity Alkenone δDs have been used successfully to reconstruct past salinity changes in the Mediterranean Sea, Black Sea, Panama Basin, and Mozambique Channel. As an extension of salinity, this data was also used to draw further conclusions about ancient environments, such as ancient freshwater flooding events, and the evolution of plankton in response to environmental changes

1Chicken was chosen as it is the most eaten animal food and it has one of the highest amount of EAAs among animal-based foods. Soybeans have the highest content of EAAs among the foods. Spirulina is a superior supplement containing the highest amount of EAAs. Another important factor is the composition of EAAs. As we can see the quantity of some EAAs is lower. For example, pumpkin seeds despite high total EAAs content have a low content of lysine. A good indication is to calculate the food sample that meets the WHO's requirement of EAAs intake. A table below shows the smallest sample food required to provide all EAAs according to the RDA for each individual EAA.

There are 25 known isotopes of potassium, three of which occur naturally: 39K (93.3%), 40K (0.0117%), and 41K (6.7%) (by mole fraction). Naturally occurring 40K has a half-life of 1.250×109 years. It decays to stable 40Ar by electron capture or positron emission (11.2%) or to stable 40Ca by beta decay (88.8%). This decay results in a relatively higher concentration of Argon in the atmosphere. The decay of 40K to 40Ar is the basis of a common method for dating rocks. The conventional potassium–argon dating method depends on the assumption that the rocks contained no argon at the time of formation and that all the subsequent radiogenic argon (40Ar) was quantitatively retained. Minerals are dated by measurement of the concentration of potassium and the amount of radiogenic 40Ar that has accumulated. The minerals best suited for dating include biotite, muscovite, metamorphic hornblende, and volcanic feldspar; whole rock samples from volcanic flows and shallow instrusives can also be dated if they are unaltered. Apart from dating, potassium isotopes have been used as tracers in studies of weathering and for nutrient cycling studies because potassium is a macronutrient required for life on Earth. 40K occurs in natural potassium (and thus in some commercial salt substitutes) in sufficient quantity that large bags of those substitutes can be used as a radioactive source for classroom demonstrations. 40K is the radioisotope with the largest abundance in the human body. In healthy animals and people, 40K represents the largest source of radioactivity, greater even than 14C.

A vaccine licensure occurs after the successful conclusion of the development cycle and further the clinical trials and other programs involved through Phases I–III demonstrating safety, immunoactivity, immunogenetic safety at a given specific dose, proven effectiveness in preventing infection for target populations, and enduring preventive effect (time endurance or need for revaccination must be estimated). Because preventive vaccines are predominantly evaluated in healthy population cohorts and distributed among the general population, a high standard of safety is required. As part of a multinational licensing of a vaccine, the World Health Organization Expert Committee on Biological Standardization developed guidelines of international standards for manufacturing and quality control of vaccines, a process intended as a platform for national regulatory agencies to apply for their own licensing process. Vaccine manufacturers do not receive licensing until a complete clinical cycle of development and trials proves the vaccine is safe and has long-term effectiveness, following scientific review by a multinational or national regulatory organization, such as the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA). Upon developing countries adopting WHO guidelines for vaccine development and licensure, each country has its own responsibility to issue a national licensure, and to manage, deploy, and monitor the vaccine throughout its use in each nation.

Sources: en.wikipedia.org

Frequently asked questions